Genmab to Present HuMax-CD4 Data at the Society for Investigative Dermatology Conference COPENHAGEN, Denmark, February 18 /PRNewswire/ -- - 67% of Early Stage and 50% of Advanced Stage Patients Obtained CA Score Reduction of at Least 50% in High Dose Group - Summary: Genmab's HuMax-CD4 Achieves Positive Interim Results in Extended Phase II Studies for CTCL Genmab A/S (CSE: GEN) announced today it will present data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th Annual Meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4 clinical trials were evaluated using the Composite Assessment of Index Lesion Disease Activity (CA) score. These patients were treated at one of three dose levels as follows: 280 mg (11 early stage and 10 advanced stage), 560 mg (9 early stage) or 980 mg (6 advanced stage). Following 280 mg, 33% of 21 patients obtained a 50% or better CA score reduction. Following 560 mg, 67% (six of nine early stage patients) obtained a CA score reduction of 50% or better, including two who obtained a 100% reduction. Three other early stage patients had stable disease. Following 980 mg, 50% (three of six) advanced stage patients obtained a CA score reduction of more than 50% and three patients had stable disease. Following 280 mg dosing, 6 grade 3 adverse events were reported by 4 patients. 5 were unrelated to HuMax-CD4. Following 560 and 980 mg, 1 unrelated grade 3 adverse event was reported. No grade 4 events were reported. HuMax-CD4 has been found to be safe and well tolerated by patients with CTCL in clinical studies to date. At present, 15 early stage patients are enrolled in the 560 mg treatment group and 10 late stage patients are enrolled in the 980 mg treatment group. At the time of the presentation on April 30, 2004, more complete data covering more of these patients for a longer period of time is expected to be available. "The higher doses of HuMax-CD4 are showing a positive effect in these studies so far," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We are pleased because there is a need for new therapy for CTCL." About HuMax-CD4 HuMax-CD4 is a high affinity human antibody that targets the CD4 receptor on T-lymphocytes. Genmab is running two Phase II studies concurrently using HuMax-CD4 to treat cutaneousT-cell lymphoma (CTCL). Disease prevalence T-cell lymphomas positive for the CD4 receptor constitute around 5% of Non-Hodgkin's Lymphomas. There are about 1,000 new cases of CTCL per year in the US and the prevalence of the disease is estimated at 16,000 to 20,000. CTCL patients tend to have a lifespan of 10 to 30 years and therefore could be treated several times during the disease progression. In addition to CTCL, approximately half of the non-cutaneous T-cell lymphomas express the CD4 receptor on their cell surface and Genmab has also treated a non-cutaneous T-cell lymphoma patient on a compassionate use basis with a good clinical effect. Considering this and the encouraging data from the CTCL study, Genmabis now making plans to initiate a study in non- cutaneous T-cell lymphoma patients in the second half of 2004, especially since these patients also have a dramatic need for new and less toxic therapies. Non-cutaneous T-cell lymphomas that arepositive for the CD4 receptor are predominantly of the nodal subtype. This includes peripheral and angioimmunoblastic T-cell lymphomas of which 75% are CD4 positive and anaplastic large cell lymphomas of which 20% are. The combined incidence of these lymphomas is approximately 2,770 in the US and Canada and 3,280 in industrialized Europe. Their prevalence in Europe is approximately 10,000 and in US and Canada it ranges from 8,000 to 10,000. Conference Call Genmab's Management will hold a conference call to discuss the HuMax-CD4 Phase II results, today, Wednesday, February 18, at 3:00 p.m. CET 2:00 p.m. GMT 9:00 a.m. US Eastern Time The dial in numbers are as follows: +1-800-915-4836 (in the US) and ask for the Genmab conference call +1-973-317-5319 (outside the US) and ask for the Genmab conference call The conference call will be held in English. About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(TM) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquarteredin Copenhagen, Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit www.genmab.com. Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements,e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Genmab is not under an obligation to update statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. Web site: http://www.genmab.com DATASOURCE: Genmab A/S CONTACT: Sisse P. Hansen, Investor & Public Relations, Genmab A/S, T: +45 33 44 77 76, M: +45 25 27 47 27, E: sha@genmab.com

Copyright